CEOs of uBiome take administrative leave following FBI raid

boardroom
The probes center on uBiome’s possible financial connections with physicians tasked with ordering its microbiome tests, as well as whether insurers were regularly double-billed or overcharged. (Pixabay)

In the days following an FBI raid of its headquarters, uBiome’s board of directors has moved to replace its pair of co-CEOs with its top lawyer, for the time being.

The sequencing test provider’s general counsel, John Rakow, will serve as interim CEO, while uBiome founders Jessica Richman and Zac Apte take administrative leave, the board said in a statement.

In addition, a special committee of the board will launch its own investigation into the company’s billing practices—joining federal and state scrutiny as well as inquiries from insurance companies.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“As interim CEO of uBiome, I want all of our stakeholders to know that we intend to cooperate fully with government authorities and private payors to satisfactorily resolve the questions that have been raised, and we will take any corrective actions that are needed to ensure we can become a stronger company better able to serve patients and healthcare providers,” said Rakow, who first joined the company last October.

RELATED: FBI raids uBiome’s San Francisco HQ over insurance billing practices: reports

The probes—thrown into the spotlight when the FBI showed up to confiscate computers at uBiome’s San Francisco offices last week—center on the company’s possible financial connections with physicians tasked with ordering its suite of microbiome-focused panels, as well as whether insurers have been double-billed or overcharged for tests.

A number of large insurers—including Anthem, Aetna and Regence BlueCross BlueShield—have been looking into the uBiome’s practices alongside the California Department of Insurance, according to The Wall Street Journal, which first reported the FBI raid.

RELATED : uBiome grabs $83M, new digs and Joe Jimenez as it expands into therapeutics

The test provider’s at-home offerings include assessments of gut bacteria wellness, chronic gastrointestinal and bowel conditions, upper respiratory infections, women’s health and sexually transmitted infections.

The company raised $83 million in a funding round late last year—from OS Fund, Y Combinator and others—to support its first steps into developing its own therapeutics, while signing on former Novartis CEO Joe Jimenez to its board of directors.

Suggested Articles

Thermo Fisher Scientific has begun early talks to take over Dutch diagnostics maker Qiagen, according to reports.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.

VistaGen responded to the failure of the ketamine-line drug by vowing to review all the data before deciding on next steps.